Arcus Biosciences upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright analyst Emily Bodnar upgraded Arcus Biosciences (RCUS) to Buy from Neutral with a price target of $24, up from $18. The ARC-20 study evaluating casdatifan monotherapy and in combo with other agents in clear cell renal cell carcinoma has enrolled 40 patients in the combo cohort, the analyst tells investors in a research note. The firm is increasingly positive on the initial data expected in mid-2025. It views current stock levels as an attractive entry point.